Eliciting universal protection against influenza
Nature Immunology
October 21, 2013
A vaccination strategy that can protect against multiple strains of influenza virus is described in a report published this week in Nature Immunology.
Influenza viruses can rapidly mutate, which allows outgrowth of strains that are not recognized by antibodies elicited by current vaccines. Thus every flu season requires vaccination against the prevalent circulating influenza viruses, though newly emerging strains may not be represented in vaccine formulation and therefore pose a potential gap in immune protection.
Maureen McGargill and colleagues find that mice immunized against the H3N2 influenza virus in the presence of rapamycin, a drug that targets the host enzyme mTOR, could elicit protective immunity to the mice when subsequently challenged with H1N1, H5N1 or the newly emergent H7N9 influenza strains. Rapamycin inhibits the generation of high-affinity antibodies against the H3N2 virus, instead eliciting immune memory and antibody responses against conserved viral sequences. Thus, using rapamycin to dampen the immune response during vaccination paradoxically improves protection against a broader range of influenza strains.
doi: 10.1038/ni.2741
Research highlights
-
Jun 29
COVID-19: Assessing instances of long COVID in UK health dataNature Communications
-
Jun 24
Palaeontology: It sucked to be the prey of ancient cephalopodsScientific Reports
-
Jun 24
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports
-
Jun 23
Scientific community: Women credited less than men in scientific paper authorshipNature
-
Jun 17
Health technology: New cost-effective smartphone test for middle ear functionCommunications Medicine
-
Jun 17
Conservation: Feral cats pushing critically endangered marsupial further towards extinctionScientific Reports